Key result
Long-term ergotamine therapy is a rare but potential cause of multivalvular heart disease, hypothesized to occur via stimulation of serotonergic receptors (5-HT2B) and myofibroblast proliferation.
Case Report
Highlights the rare but significant risk of multivalvular heart disease associated with long-term ergotamine therapy.
May prompt ergotamine exposure review in unexplained multivalvular disease; leaves open incidence and causality in larger cohorts.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kantartzis et al. (2013) conducted a case report in Ergotamine-Induced Multivalvular Heart Disease. Ergotamine therapy was evaluated on Valvular heart disease. Long-term ergotamine therapy is a rare but potential cause of multivalvular heart disease, hypothesized to occur via stimulation of serotonergic receptors (5-HT2B) and myofibroblast proliferation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: